Illustration: Assistant Editor Kathy Wong for Endpoints News

Drug name re­view: Sci­ence takes the spot­light in 2022

Sci­ence was the name of the game in phar­ma drugs last year — lit­er­al­ly. FDA-ap­proved drug names in 2022 leaned heav­i­ly on sci­ence as­so­ci­a­tions, ac­cord­ing to ex­perts. While that’s not un­usu­al, in a year of few­er ap­provals than any in the past six years, the over­all nam­ing con­ven­tions more of­ten re­called fa­mil­iar strat­e­gy than break­out sur­prise.

Why? One of the lead­ing rea­sons is that it’s just hard­er to come up with unique, at­tribute-re­lat­ed names. In part, that’s be­cause they’ve al­ready been trade­marked and are off-mar­ket, while the FDA is more dis­cern­ing about the overt use of prod­uct at­trib­ut­es or po­ten­tial ben­e­fits in brand names.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.